Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Apatinib for the treatment of gastric cancer.

Literature DB >> 25420417

Apatinib for the treatment of gastric cancer.

Abstract

INTRODUCTION: Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib mesylate, a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has been recommended as third-line treatment for metastatic gastric cancer patients. AREAS COVERED: The current review summarizes the publications and conference reports relating to apatinib from preclinical and clinical research in gastric cancer. Apatinib showed good safety, tolerance and treatment efficacy in Phase I/II studies. In a Phase III study, apatinib prolonged the median overall survival of patients with chemotherapy-refractory metastatic gastric cancer by 55 days and the median progression-free survival by 25 days compared with placebo. EXPERT OPINION: Apatinib is a new treatment option for advanced gastric cancer. Apatinib is expected to have a broader application when it has been evaluated worldwide. The key issues are to find biomarkers and overcome drug resistance.

Entities: Chemical Disease Species

Keywords: VEGF receptor-2; apatinib; stomach neoplasms; tyrosine kinase inhibitor

Mesh：

Substances：

Year: 2014 PMID： 25420417 DOI： 10.1517/14656566.2015.981526

Source DB: PubMed Journal: Expert Opin Pharmacother ISSN： 1465-6566 Impact factor: 3.889

Keyword Cloud
Cited

55 in total

10. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.

Authors: Mingming Yu; Zhiwei Gao; Xiaojian Dai; Hui Gong; Lianshan Zhang; Xiaoyan Chen; Da-Fang Zhong; Sherwin K B Sy
Journal: Clin Pharmacokinet Date: 2017-01 Impact factor: 6.447

Apatinib for the treatment of gastric cancer.

Review 1. Targeted therapy for advanced gastric cancer: A review of current status and future prospects.

2. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.

3. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.

Review 4. Progress in the treatment of solid tumors with apatinib: a systematic review.

Review 5. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.

6. [Inhibitory effect of apatinib on HCT-116 cells and its mechanism].

Review 7. New advances in targeted gastric cancer treatment.

8. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer.

Review 9. Changing strategies for target therapy in gastric cancer.

10. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.